Breast Cancer Markers: Vimentin, p53, and EGF-R
Author Information
Author(s): G. Cattoretti, S. Andreola, C. Clemente, L. D'Amato, F. Rilke
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori
Hypothesis
The study investigates the expression of p53, vimentin, and EGF-R in estrogen receptor-negative breast carcinomas.
Conclusion
The study found that p53, vimentin, and EGF-R are significantly expressed in estrogen receptor-negative breast cancer cases.
Supporting Evidence
- 51.1% of ER-ICA negative cancers were p53 positive.
- 57.8% of ER-ICA negative cancers were vimentin positive.
- 60% of ER-ICA negative cancers were EGF-R positive.
- Only 5.3% of ER-ICA positive tumors were p53 positive.
- 80% of ER-ICA negative carcinomas were positive for at least one of the markers.
Takeaway
This study looked at breast cancer and found that certain proteins are more common in a type of cancer that doesn't respond to estrogen, which might help doctors understand how to treat it better.
Methodology
The study analyzed 196 primary breast cancer specimens for the expression of p53, vimentin, and EGF-R using immunohistochemistry.
Limitations
The study may have limitations related to the sensitivity of the techniques used to detect protein expression.
Participant Demographics
194 female and 2 male patients aged 23-86 years, mean age 53.04.
Statistical Information
P-Value
P<0.0001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website